N
NRIX icon

Natixis’s Nurix Therapeutics NRIX Stock Holding History

Natixis’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,706
Closed -$51K – 1137
2024
Q4 		$51K Sell
2,706
-515
-16% -$11.8K ﹤0.01% 882
2024
Q3 		$72.4K Sell
3,221
-408
-11% -$9.24K ﹤0.01% 766
2024
Q2 		$75.7K Sell
3,629
-1,154
-24% -$18K ﹤0.01% 758
2024
Q1 		$70.3K Sell
4,783
-689
-13% -$7.41K ﹤0.01% 805
2023
Q4 		$56.5K Sell
5,472
-288
-5% -$1.97K ﹤0.01% 811
2023
Q3 		$45.3K Sell
5,760
-19
-0.3% -$173 ﹤0.01% 830
2023
Q2 		$57.7K Sell
5,779
-1,301
-18% -$13.3K ﹤0.01% 834
2023
Q1 		$62.9K Sell
7,080
-441
-6% -$4.6K ﹤0.01% 812
2022
Q4 		$82.6K Buy
+7,521
New +$90.7K ﹤0.01% 890
2022
Q1 		– Sell
-7,970
Closed -$231K – 1275
2021
Q4 		$231K Sell
7,970
-526
-6% -$15.9K ﹤0.01% 1154
2021
Q3 		$255K Buy
+8,496
New +$262K ﹤0.01% 1120

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Natixis's NRIX Position: Q1 2025 in Review

Natixis sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 2,706 shares — an estimated $51K sold.

Natixis first reported a position in NRIX in Q3 2021 and held it in 11 quarters. The position peaked at $255K in Q3 2021. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

  • Natixis reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Natixis sold 2,706 Nurix Therapeutics shares in Q1 2025, an estimated $51K.
  • Natixis first reported a position in Nurix Therapeutics in Q3 2021 and held it in 11 quarters.
  • Natixis's Nurix Therapeutics position peaked at $255K in Q3 2021.
  • 170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on Natixis's 13F filing for Q1 2025, filed 14 May 2025.